



ASX Circular

Date: 12 February 2010

Key topics

1. CBio Limited
2. ASX code: CBZ, CBZO
3. Quotation expected to commence on Monday, 15 February 2010 at 11.00 am AEDT

Reading List

Banks
 Client Advisers
 Compliance Managers
 Corporate Advisory
 DTR Operators
 Issuers
 Institutions
 ASTC Participants
 Operations Managers (back office)
 Share Registries
 ACH Participants
 Market Participants

Authorised By

Andrew Black

Contact

Kim-Ly Nguyen

ASX Limited
 ABN 98 008 624 691
 Exchange Centre
 20 Bridge Street
 Sydney NSW 2000
 PO Box H224
 Australia Square NSW 1215

Internet: <http://www.asx.com.au>

No responsibility is accepted for any inaccuracies contained in the matter published.

CBIO LIMITED – COMMENCEMENT OF OFFICIAL QUOTATION

CBio Limited (the "Company") was admitted to the Official List of ASX Limited ("ASX") on Wednesday, 10 February 2010.

Official quotation of the Company's securities are expected to commence on Monday, 15 February at 11.00 am AEDT.

<u>Quoted Securities</u>	60,521,564 ordinary shares each fully paid 4,506,895 options exercisable at \$1.00 each on or before 31 December 2012
<u>ASX Code:</u>	CBZ CBZO
<u>Time & Date:</u>	11.00 am AEDT, Monday, 15 February 2010
<u>ITS Abbreviation:</u>	CBIO
<u>ISIN:</u>	AU000000CBZ4 AU000000CBZO0
<u>Home Branch:</u>	Sydney
<u>Industry Classification:</u>	GICS 3520: Pharmaceuticals & Biotechnology
<u>Registered Office:</u>	Brisbane Technology Park 85 Brandl Street Eight Mile Plains QLD 4113
<u>Place of Incorporation:</u>	Queensland
<u>Company Secretary:</u>	Ben Graham
<u>Share Registry:</u>	Link Market Services Ltd Level 19 324 Queen Street Brisbane QLD 4000
<u>Balance Date:</u>	30 June
<u>CHESS:</u>	Participating. The Company will also operate an issuer sponsored sub-registry.
<u>Dividend Policy:</u>	Refer to page 53 of the Company's prospectus dated 10 November 2009.

ASX restricted securities (not quoted):

3,359,744 ordinary fully paid shares, classified by ASX as restricted securities and to be held in escrow for a period of 24 months from commencement of official quotation.

11,597,253 ordinary fully paid shares, classified by ASX as restricted securities and to be held in escrow for a period of 12 months from the date of issue.

15,087,494 options exercisable at \$1.00 each on or before 31 December 2012, classified by ASX as restricted securities and to be held in escrow for a period of 24 months from commencement of official quotation.

4,780,460 options exercisable at \$1.00 each on or before 31 December 2012, classified by ASX as restricted securities and to be held in escrow for a period of 12 months from the date of issue.

Securities not quoted:

710,000 options exercisable at \$2.00 each on or before 31 December 2012.

600,000 options exercisable at \$3.00 each on or before 31 December 2012.

Activities:

Development and commercialisation of treatments for autoimmune diseases.

For further information please refer to the Company's prospectus dated 10 November 2009, supplementary prospectus dated 7 December 2009 and further supplementary prospectus dated 22 December 2009.